Abstract | When Ralph Steinman and Zanvil Cohn first described dendritic cells (DCs) in 1973 it took many years to convince the immunology community that these cells were truly distinct from macrophages. Almost four decades later, the DC is regarded as the key initiator of adaptive immune responses; however, distinguishing DCs from macrophages still leads to confusion and debate in the field. Here, Nature Reviews Immunology asks five experts to discuss the issue of heterogeneity in the mononuclear phagocyte system and to give their opinion on the importance of defining these cells for future research.
Frédéric Geissmann. Most cells types in the body are identified by their origin, anatomical location, function, and pheno type. Myeloid cells are arguably no more heterogeneous than other cell types (such as lymphoid cells or epithelial cells), and therefore heterogeneity may not be solely responsible for the confusion between macrophages and DCs.
Confusion has arisen in part from the use of nonspecific cell surface markers, such as CD11c (also known as αX integrin), as a surrogate for function, anatomical location, and lineage. This has led to the name 'DC' being used for several cell types, including bona fide classical DCs, as well as activated monocytes, tissue macro phages, interferon (IFN)producing cells and even some natural killer (NK) cells and eosinophils.
Recent in vivo experiments in mice have increased our understanding of the develop ment and functions of DC and macrophage subsets 1, 12, 15, 64, 65 and should reduce confu sion. However, despite this progress in mice, corresponding human subsets are yet to be characterized. Numerous studies have attempted to recapitulate some of the hetero geneity of human DCs and macrophages in vitro. However, in vitro differentiation of blood monocytes or bone marrow cells does not recapitulate in vivo differentiation. For example, Langerhans cells and microglial cells may not renew from bone marrow [2] [3] [4] . Siamon Gordon. As far as mononuclear myeloid cells are concerned, I recognize a family of closely related cells with a common origin, which branches into irreversibly dif ferentiated sublineages, such as macrophages, DCs and osteoclasts
.
Part of the confusion in the field arises from the adaptability and plasticity of macrophages. As a result of their extensive receptor repertoire and versatile biosynthetic capacity, they are highly responsive to the microheterogeneity present in different tissue environments 6 . Furthermore, follow ing constitutive or inflammationinduced migration between different compart ments of the body, they undergo marked phenotypical modulation 7 . Even in the absence of inflammation and infection, macrophage populations 8 display bewildering heterogeneity. For example, numerous mono nuclear phagocyte populations are found in the mouse spleen, including red and white pulp macrophages, 'reservoirs' of mobilizable monocytes 9 , marginal zone metallophilic macrophages and outer zone macrophages, and further complexity arises from the presence of resident, motile and migratory activated DCs in the same organ 10 .
Another problem is the marked hetero geneity in the turnover and variable lifespan of macrophages -hours to weeksdepending on stimulation, programmed cell death and/or injury. In the mouse, genetic manipulation and intravital imaging methods make it possible to study direct precursor-product relationships. However, the dynamics of tissue populations in humans remain largely unexplored.
Gwendalyn J. Randolph. Yes, there is confusion. However, I think the confusion can be resolved when the right considera tions are given. First, confusion should be minimal when spleen and lymph nodes are considered. In these locations, where his torically the pioneering work on DCs and to some extent macrophages has centred, it is clear that CD11c hi mononuclear phago cytes are DCs rather than macrophages. An abundance of recent evidence confirms that spleen and lymph node DCs are function ally distinct from macrophages, do not arise from monocytes, and share fewer properties with monocytes than macrophages do [11] [12] [13] [14] [15] [16] [17] . So here is where I see the contemporary confusion arising. DCs and macrophages in nonlymphoid organs are poorly character ized compared with their lymphoid tissue counterparts. At last, work in vivo on macro phage and DC biology in nonlymphoid organs is intense. Many of us have assumed that the same set of markers that defini tively distinguish DCs from macrophages in lymphoid organs will also apply in non lymphoid organs, but it is turning out that this premise is not true. So, I think the main confusion arises when scientists assume that what is true in lymphoid organs is also true in nonlymphoid organs and what is true under v i e w p o i n t
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homeostatic conditions is also relevant in inflammation. None of these lines should be blurred until we know more about these won derful populations in different anatomical sites and tissue states.
David A. Hume. The mononuclear phago cyte system is a family of cells derived from a committed progenitor in the bone mar row 18 . The number of subpopulations of mono nuclear phagocytes one can define is an exponential function of the number of mark ers examined 19 ; the heterogeneity is essen tially infinite because each gene has its own intrinsic probability of being expressed 20 .
It is clear that the definition of DCs has changed with time. The original description of DCs described them as not actively endo cytic and not part of the mono nuclear phago cyte system 18, 19 . CD11c, the favoured DC marker, was already known to be expressed by most tissue macrophages before the use of CD11creporter transgenes as markers of DCs, and of CD11c-DTR (diphtheria toxin receptor) mice to 'selectively' ablate them 19, 21 . Subsequently, cells that were morphologi cally and functionally active phagocytes were found to 'convert' into DCs 22 . This led to the concept of the immature DC and then of inflammatory or tumour necrosis factor and inducible nitric oxide synthase-producing DC (TIP DC) 23 . As noted also by G.j.R, there is no obvious distinction between these cells and resident or classically activated macrophages, respectively.
If we consider the DC, as originally defined by Ralph Steinman and Zanvil Cohn, it was defined functionally by its ability to stimulate in an allogeneic mixed leukocyte reaction (MlR) 24 , and the distinction from a macrophage is clear. These DCs do not express the widely studied macrophage marker F4/80 (also known as EMR1), CD11b (also known as αM integrin) or Fc recep tors, they are not phagocytic and they do not adhere to fibronectin; we used these criteria to isolate this form of DC from the intes tinal lamina propria 25 . As for the rest, most mononuclear phagocytes in the gut wall, for example, are monocytederived, F4/80 + and express the macrophage colonystimulating factor 1 receptor (CSF1R; also known as CD115) and all the known endocytic recep tors [26] [27] [28] ; they have even been said to 'resemble macrophages' 26 . But they have been termed DCs solely because they express CD11c. And that really does confuse the field.
Allan m. mowat. In my own field of mucosal immunology, myeloid cell hetero geneity has led to considerable confusion, and many accepted truths probably need to be reinterpreted. In the gut, there are extraordinary numbers of cells of myeloid origin present in the absence of inflamma tion. There is a consensus that both macro phages and DCs in the gut are generally hyporesponsive 29, 30 , 27, 29, [32] [33] [34] . Almost with out exception, it is claimed that specific DC or macrophage populations may be respon sible for these diverse properties, and it is implied that these could be manipulated spe cifically for practical purposes, such as vac cine development and disease therapy. Many of these socalled DC subsets are not clearly defined and it is essential to understand that different groups use different methods to obtain and characterize DCs. often the starting populations are preselected on the basis of arbitrarily defined levels of expres sion of markers that have been assumed to be specific for either DCs or macrophages, but are actually expressed by both 35 . Similar reservations cast doubt on the widely accepted view that a specific popu lation of DCs can take up antigens from the intestinal lumen by sending processes through the epithelium 36, 37 elegant imaging data, these findings pro voked great interest throughout the field and in the wider immunological commu nity. Textbooks describe the phenomenon, and many experimental studies on vac cines, inflammation or infection rely on it as a starting paradigm. However, these DCs have been characterized entirely by their expression of CX 3 Cchemokine receptor 1 (CX 3 CR1) and MHC class II, rather than on any functional criteria. In fact, these cells seemingly cannot migrate to draining lymph nodes, or present antigen to specific T cells 35 . I think that these 'sampling' cells may be tissueresident macrophages, contributing little or nothing to shaping primary T cell responses and being responsible more for scavenging functions in the mucosa itself. These are distinct properties, and it is now essential that all previous work in the field is reexamined taking into account the most recent advances in phenotyping and functional characterization. Similar over laps are emerging from studies of myeloid subsets previously thought to be distinct populations in lung, skin and other organs.
Are there any good phenotypical markers for DCs and macrophages, or should the distinction be based solely on function? If so, what does a DC do that a macrophage can't and vice versa?
G.J.R. Generally, cells with high surface levels of F4/80 are macrophages, but lower levels of F4/80 are commonly observed on DCs. Furthermore, much has been made of CD11c as a marker for mouse DCs but, as mentioned above, the accuracy of this marker as a means to track DCs depends on the anatomical site in question. Myeloid cells with high levels of CD11c, though not those with low to inter mediate CD11c, are DCs in lymphoid organs. However, in the lung, high levels of CD11c are found on macrophages 38, 39 , and there are plenty of other anatomical locations outside of lymphoid organs where macro phages are CD11c + . Moreover, CD11b was once thought to be a universal, albeit not specific, marker for macrophages. However, it turns out that splenic macro phages are CD11b low or negative 40 , as are pulmonary macrophages 38, 39 . There are a handful of Ctype lectins that seem to be specifically expressed by DCs, but there is currently not enough knowledge to make definitive claims about any marker combination, especially in nonlymphoid compartments.
Perhaps the best functional attribute I can think of to distinguish DCs and macro phages is the property of DCs to localize in the T cell zone of lymphoid organs where they can stimulate T cells. This attribute combines several features that DCs seem to specialize in -potent, though not exclu sive, ability to activate T cells and the ability to migrate into the T cell zone itself. Indeed, if I can paraphrase a comment I heard from Marc jenkins (personal communication): one of the landmark contributions brought about by Ralph Steinman's discovery of DCs was how it highlighted the specialized nature of the T cell zone. 
CD11c
+ cells that sample the intesti nal lumen (socalled lamina propria DCs) 36, 41 do not obviously migrate to mesenteric lymph nodes efficiently 26, 39 is one reason why these cells may be better classified as macrophages instead of their present classification as DCs.
In the long term, functional properties such as antigen processing and presentation or migration are too fluid to serve as strict barriers for giving a cell its name. ongoing and future developments will make it possible to define DCs and macrophages by lineage. Classification according to lineage would somewhat disrupt the current functional and markerbased classification. For example, we know that monocytederived cells can develop properties of DCs, including potent antigen presentation and migratory abilities, and we currently call some monocytederived cells DCs. Nonetheless, I think that the best solution to integrating DC and macrophage biology in the future is to define DCs as those cells that arise from dedicated DC precursors that we know exist 17 , but which need more characterization and study, and to define macrophages as those cells that descend from either embryonic macrophages or blood monocytes. Communicating science is obvi ously easier when cells have a fitting name, but we shouldn't be afraid to let the names evolve to fit contemporary advances in our knowledge and to ultimately make further classification easier as the field advances.
Glossary

CD11c-DTR (diphtheria toxin receptor) mice
Mice genetically engineered to express the diphtheria toxin receptor under the control of the CD11c promoter. Following administration of diphtheria toxin, cells expressing CD11c are transiently depleted in these animals. These mice have typically been used to study DC function, but certain CD11c + macrophage populations are also depleted by diphtheria toxin treatment.
Cross-presentation
The mechanism by which certain APCs take up, process and present extracellular antigens on MHC class I molecules to stimulate CD8 + T cells. This property is atypical, as most cells exclusively present peptides derived from endogenous proteins on MHC class I molecules.
Kupffer cell
A specialized macrophage that lines the sinusoidal vessels of the liver. These cells regulate local immune responses, and remove microbial particles, endotoxin and other noxious substances that penetrate the portal venous system.
Langerhans cell
A type of DC that is resident in the epidermal layer of the skin.
M1 macrophages
A macrophage subtype that produces pro-inflammatory cytokines and has cytotoxic functions.
M2 macrophages
A macrophage subtype that acts to dampen inflammatory responses and scavenge debris, as well as to promote angiogenesis and tissue remodelling and repair.
Marginal zone metallophilic macrophage
A type of macrophage that surrounds the splenic white pulp, adjacent to the marginal sinus, and is involved in trapping particulate antigens.
Microglial cell
A phagocytic cell of myeloid origin that is involved in the innate immune response in the central nervous system. Microglial cells are thought to be the brain-resident macrophages.
Mixed leukocyte reaction (MLR)
. A tissue-culture technique for testing T cell reactivity and APC activity. A population of T cells is cultured with MHC-mismatched APCs, and proliferation of the T cells is determined by measuring the incorporation of 3 H-thymidine into the DNA of dividing cells.
Myeloid-derived suppressor cells
(MDSCs). A group of immature CD11b + GR1 + cells (which include precursors of macrophages, granulocytes, DCs and myeloid cells) that are produced in response to various tumour-derived cytokines. These cells have been shown to induce tumour-associated antigen-specific CD8 + T cell tolerance.
Osteoclast
Multinucleated giant cells, of myeloid origin, that are responsible for bone resorption. Osteoclasts degrade bone matrix and solubilize calcium from bone.
Plasmacytoid DCs
An immature DC with a morphology that resembles that of a plasma cell. Plasmacytoid DCs produce type I IFNs in response to viral infection.
Tumour necrosis factor and inducible nitric oxide synthase-producing DC (TIP DC). Monocyte-derived DCs that produce high quantities of tumour necrosis factor and nitric oxide. These cells develop in mice from GR1 + monocytes during infection with certain bacteria, such as Listeria monocytogenes, or following myocardial damage.
A.m.m. The big problem we all encounter is that the conventional markers used to identify macrophages and DCs in mice, such as F4/80, CD11c, CD11b and MHC class II, have turned out not to be specific. This seems to be even more of an issue in tissues such as the respiratory tract and intestine, where the immunological environment is different to lymphoid tissue and there is continual antigen exposure.
Recent work shows that CD103 (also known as αE integrin) and CX 3 CR1 expres sion define distinct populations of myeloid cells in the intestinal mucosa, although the exact nature of some of the subsets identified is contentious 26 
However, recent evidence indicates that macrophages can migrate, and that langerhans cells are not important for T cell priming 44 . Also, although some macrophages (for example, Kupffer cells) are actively phagocytic, other macrophages (for example, microglial cells) show only weak phagocytic ability. So we do not really have any good functional criteria for defining macrophages and DCs as they represent not just two distinct populations, but various cell types.
S.G.
There is no single morphologic or pro tein marker of macrophages or DCs which is unambiguous. CD11c expression, for exam ple, is also abundant on alveolar macro phages, yet these cells have poor expression of F4/80, a widely used mouse macrophage antigen marker. Additionally, the F4/80 anti gen is readily detected on immature DCs, although it is downregulated on DCs after maturation. CD11b can be present or absent on tissue macrophages in situ.
Commonly, high constitutive expression of MHC class II is used to define mature DCs in the mouse. Resident macrophages in the mouse do not express MHC class II antigens until they are activated by IFNγ. However, MHC class II is constitutively present on human tissue macrophages, even in the absence of overt infection.
Although flow cytometry has been of great help in defining lymphocyte hetero geneity, embedded tissue macrophages are fragile and difficult to isolate from solid organs, even after enzymatic tissue diges tion. In situ immunochemistry is an art and a qualitative tool, sensitive to fixation condi tions, even with amplification and retrieval methods, especially when monoclonal antibodies are used. Functional analysis is a sine qua non for defining DCs, but it does not lend itself to singlecell studies.
Not enough attention has been paid to the expression of antimicrobial effector mol ecules, such as lysozyme 45 , which is abun dant in neutrophils and also readily secreted by monocytes and macrophages, but is only poorly expressed, if at all, by DCs. It is hoped that microarray and proteomic analysis will yield new markers to detect proteins that distinguish macrophages from DCs, both in mice and in humans. However, no single set of markers can be expected to apply to all stages of cell differentiation and activation.
In characterizing macrophages and DCs, I like to use the analogy of a surviving text fragment attributed to Archilocus, a Greek philosopher, and made famous by Isaiah Berlin 46 among others: "The fox knows many things, the hedgehog knows one big thing". To my mind, the macrophage is the fox, able to carry out a several functions, whereas the DC is specialized for one big function, namely to activate naive T lymphocytes 10 . 26 . It is not clear that this assay has the same APC requirements as the MlR.
D.A.H.
The problem really arises with in vitro assays 21 . In my opinion, macrophages as some define them are actually mixtures of stimulatory and inhibitory cells from dif ferent areas of the primary organs, whereas DCs are a minor population of cells exclu sively from the stimulatory end of the Not enough attention has been paid to the expression of antimicrobial effector molecules myeloid APC continuum 21 . The unique function is actually at the 'macrophage' end of this continuum; I think that these are the cells that generate T cell tolerance. The DC believers term macrophages that can suppress T cell responses 'tolerogenic' DCs 47 ! So, the problem is one of nomenclature. The term DC should be used exclusively for the APCs that reside in T cell areas of spleen and lymph node and the small numbers of similar cells at mucosal surfaces. All the con tributors agree that these cells are not phago cytic, and probably not descended from cells that ever were phagocytic. we simply need to accept that some macrophages, defined by origin, CSF1dependence in vivo, markers -such as F4/80, CD11b and Fc receptorsand phagocytic activity, can in fact present antigen to naive T cells and the controversy evaporates.
What culture conditions should a researcher use to generate macrophages and DCs? How do the in vitro-generated and in vivo cells compare?
A.m.m. like others, we use the simple and conventional methods of growing bone mar row cells in either granulocyte-macrophage colonystimulating factor (GMCSF) or CSF1 (also known as MCSF) to obtain mouse DCs and macrophages, respectively. These meth ods have the advantage of generating reason ably homogeneous and reliable numbers of cells which can be manipulated in vitro.
However, the cells obtained are probably not representative of their counterparts in tis sues. Their early stage of differentiation and homogeneity are unlikely to be replicated in vivo. More importantly, they have not been exposed to any of the environmental factors known to regulate myeloid cell differentia tion and function in tissues. For example, DCs and macrophages in the intestine show many unusual properties compared with their equivalents in other tissues, blood or bone marrow and these are known to be conditioned by local factors 29, 30, 48 . However, the mediators involved are still being identi fied and no in vitro conditions have yet been found that replicate the full characteristics of the populations in situ. The same issues apply to other tissues, and so real advances will only be made using cells isolated from the organs themselves.
F.G.
DCs obtained in culture from mono cytes or bone marrow precursor cells exist in two functionally and phenotypically distinct states, immature and mature. Fundamental progress in understanding the cell biology of antigen presentation and the cellular mecha nisms that allow DCs to initiate immunity or promote tolerance has been made using these cells 49 . Macrophages can also be obtained from monocytes or bone marrow precursors fol lowing culture with CSF1. This experimental model has allowed investigators to identify cytokines and bacterial products that control their effector functions. M1 macrophages, the prototypical activating stimuli of which are IFNγ and lipopolysaccharide (lPS), exhibit potent microbicidal properties, whereas M2 macrophages support T H 2type effector functions and may play a role in resolving inflammation through endocytic clearance and trophic factor synthesis 50 . However, the heterogeneity of the mono nuclear phagocyte system is poorly recapitu lated by these in vitro models. In other words, in vitrogenerated macrophages and DCs, albeit useful to study the cell biology of phago cytosis and antigen presentation, for example, do not represent a model to study the special ized functions of the diverse cell types that are present in vivo, or the regulation of their devel opment and functions by the tissue micro environement. As an example, many tissue macrophages and DC subsets do not derive from blood monocytes, and some may not even derive from the bone marrow 1, 4 . In vivo studies are required to analyse the functions of the mononuclear phagocyte system.
D.A.H. Individual colonies produced in vitro
from bone marrow in GMCSF contained classical DCs as well as granulocytes and macrophages 51 . Bone marrow contains a common progenitor (the macrophage and DC progenitor (MDP) 52 ), and a socalled common DC progenitor (CDP) 15 . CDPs are probably identical to highproliferative potential colonyforming cells (HPPCFC) that require more than one factor to pro duce colonies 19 . There are at least seven cytokines that one should consider in studying myeloid APC differentiation; CSF1, GMCSF, granulocyte colonystimulating factor (GCSF), Il3, FMSrelated tyrosine kinase 3 ligand (FlT3l), Il4 and IFNγ.
A dogma has emerged that cells grown in GMCSF are DCs, and those grown in CSF1 are macrophages 19 , but cells grown in both of these conditions are phagocytes and have been studied as functionally distinct macro phages 53 . Both cell types are in vitro artefacts; in vivo, progenitors do not encounter any of these factors in isolation, and there are no obvious in vivo counterparts to the in vitro derived cells. HPPCFCs require a combina tion of Il3, GMCSF, CSF1 and IFNγ for optimal proliferation to differentiate into macrophages 19 . Although DCs were origi nally thought to be CSF1independent, this is clearly not the case 54 and antibody against CSF1R is now used for the purification of DC progenitors 15 . FlT3, the receptor for FlT3l, is a marker for haematopoietic stem cells and com mon myeloid progenitors, and it is retained on classical DCs in the spleen. FlT3l can expand myeloid APC populations in vitro and in vivo 15 but, like CSF1, probably acts on the HPPCFC in combination with other factors.
G.J.R.
DCs and macrophages derived in culture show functional properties generally consistent with their counterparts in vivo. However, they are only approximations of cells that exist in vivo. They are useful for cell biological studies, for migration stud ies to some extent and in some cases they hold valuable promise as agents of cellbased immune therapies. Cultured DCs fuelled the growth of the DC field in the mid1990s, so they are historically important. Now, the DC field has moved beyond this phase and makes use of cultured DCs in combination with in vivo models. Generally, DCs cultured in GMCSF are thought to be counterparts of inflammationderived DCs, but this needs to be formally shown.
I have less experience with cultured macrophages. Perhaps they are overused in studies of M1 and M2 polarization states, and peritoneal macrophages isolated by peri toneal lavage may too often be thought to model macrophages from any anatomic site.
However, overall, I think the field appro priately uses cultured DCs and macrophages without overextending the interpretation of the data generated from them.
S.G.
The ability to generate large numbers of DCs from mouse bone marrow and from human blood monocytes with the aid of growthfactor cocktails has proved irresist ible to investigators for obvious reasons; for example, the direct isolation of these cells from blood and tissues is tedious and often results in poor yields and the introduction of artefacts.
less well appreciated is the rapid 'accul turation' of macrophages that occurs ex vivo. Kupffer cells, for example, do not express CD11b in situ, but rapidly acquire this com plement receptor in cell culture. Even modi fying culture vessels with media and growth factors cannot prevent this artefact of isola tion. Alveolar macrophages are round and loosely adherent in vivo, but are profoundly altered in morphology by adherence to tissue culture plastic, as are all macrophages. The use of undefined, nonphysiological supplements such as fetal bovine serum is particularly egregious, and defined media should be used wherever possible.
In situ analysis is therefore mandatory, but DCs and macrophages in the tissue can be difficult to access, quantify or test func tionally. Therefore an integrated approach, with appropriate awareness of artefact, is required. My own fantasy is to be able to rec reate the full panoply of macrophage pheno types observed in vivo, from embryonic stem cells and other haematopoietic stem cells, entirely in vitro. This will require knowing their in situ phenotype in detail and elucida tion of the cellular and extracellular environ ment in different organs, such as the liver, gut, lung, brain and uterus. [18] [19] [20] [21] , that all cells of the mono nuclear phagocyte system can interact with T cells. It does not matter whether they are called macrophages or DCs, what matters is the outcome of their interaction in a patho logical or therapeutic context. Antigen presentation is a regulated function. we can manipulate APC activity empirically using adjuvants such as microbial products or various cytokines. There are no mark ers that predict in vivo APC function other than high expression of MHC class II and costimulatory molecules and cytokine expression. By purifying out the suppressive 'macrophages' , we may succeed in getting a population of DCs that is more effective in a particular T cell activation assay in vitro, but classical DCs are a small subset of the potential APCs. Most of the active APCs for adoptive immunotherapy are in the macrophage fraction 21 . I think that it is not possible to define macrophages and DCs as separate entities; they are a continuum of progeny of a com mon precursor. The suggestion that DCs are a separate lineage is clearly wrong 20 . The DCs defined by Steinman and Cohn are cells of the mononuclear phagocyte system that occupy a particular niche in lymphoid tissues, no more or less unique than the spe cialized cells of the mononuclear phagocyte system found in other organs (for example, Kupffer cells and microglia). At mucosal surfaces, mononuclear phagocytes are adapted to sample, process and present anti gen. There is an almost complete overlap between expression of MHC class II and the macrophage marker F4/80 in mononuclear phagocytes found in mucosal sites 55 . More progress would be made by focusing on the functions on genes and gene products; the infinite subdivision of myeloid cells using multicolour flow cytometry with arbitrary gates is a futile and unproductive avenue for future research.
How important is the issue of defining macrophages and DCs for future research and potential immune therapies?
D.A.H. It is my view, discussed in detail elsewhere
F.G.
Because macrophages and DCs con sist of several cell types with discrete and essential functions, defining the develop ment and functions of these cells in their natural in vivo context (particularly in humans) is essential for our understanding of innate and adaptive immune response, and is therefore necessary to improve treat ments for inflammatory and infectious diseases, as well as for cancer. The success of modern vaccines and immune therapies has already benefited from an improved knowledge of macrophage and DC biol ogy 56 . Increasing our understanding of the functions of human macrophages and DCs in vivo is likely to be crucial for the design of new therapeutic approaches, but this task is challenging.
one of the key challenges is to translate knowledge from mouse studies to the human system. For example, we, and others, have proposed that mouse GR1 + monocyte derived TIP DCs 23 A number of therapies are already being developed that target DC surface molecules, and it could be equally useful to apply simi lar strategies to the phenotypic subsets of DC which seem to have distinct functions or which operate in different tissues. The CD103 + population of intestinal DCs is an excellent example of this, as it has a crucial role in shaping mucosal immune responses by the generation of gut homing T Reg cells 29 
.
In the skin, an apparently similar subset can potently cross-present antigens to CD8 + T cells 59 . These properties are being explored as targets for vaccination or induction of tolerance.
Conversely, macrophages may be more important to target for their proinflamma tory and catabolic functions, without neces sarily interfering with the initiation phase of immune responses. For all these reasons, establishing celltype specific phenotypic or functional markers will be essential.
S.G.
Macrophages and DCs provide attrac tive targets for therapy. Selective targeting of recruited or resident DCs or macrophages, or of effector cytokines, should not incapacitate the entire innate defence system against path ogens or disrupt the homeostatic functions of macrophages. The ability to harness DC antigenpresentation through enhanced vac cination strategies could transform tumour immunization and overcome lymphoid and myeloid suppressor mechanisms.
The increased understanding of pattern recognition receptor signalling will aid the development of better adjuvants to boost adaptive immune responses. Targeting immunogens to particular DC subsets (for example, through the use of monoclonal it is not possible to define macrophages and DCs as separate entities; they are a continuum of progeny of a common precursor antibodies specific for molecules such as DEC205 (also known as ly75) 60 ) has shown promise in mouse models, although much more work is required to confirm these studies in primates and humans. longacting inducers of DC typeI IFN production, such as the TlR3 ligand polyinosinic-polycytidylic-polyllysine (poly I:C:lC), need further evaluation 61 .
To be practical and effective, I think that it is necessary to target specific subsets of DCs or macrophages in vivo, rather than by ex vivo manipulation and subsequent adoptive transfer of cells. The ability to do so safely will depend on an improved knowl edge of the molecular basis of mononuclear myeloid cell heterogeneity in vivo.
G.J.R.
Both macrophages and DCs have cru cial roles in events that influence immunity, health of tissues, and recovery from disease states. I don't see how research on any cell type can occur optimally without further defining the cell of interest, and all cells have to be called something.
Right now, a limitation to progress in immunology -and by extension, immuno logical therapies -is that DC and macrophage biologists don't talk with each other enough. Indeed, if a cell is called a DC in a paper, I think that it is less likely that a macro phage biologist will read it and vice versa. If a neu tral term is used in a paper, such as 'CD11c + cell' 62 or 'antigenpresenting cell' , this may also limit or alter its impact by limiting the ability of the right scientists to find it.
Matt Collin, whose work focuses on human DCs and macrophages 63 , has sug gested to me that M1 or classically activated macrophages are probably the same cells as TIP DCs (M. Collin, personal communica tion). Indeed, I cannot find any instance where the same study shows both cell types in the same place. This is just one example of how further work and open dialogue in defining macrophages and DCs could lead to a clearer and more comprehensive body of literature for all scientists. That, in turn, can only help to advance the field.
DC and macrophage biologists don't talk with each other enough. Indeed, if a cell is called a DC in a paper, I think that it is less likely that a macrophage biologist will read it and vice versa
